Treating unresectable intrahepatic cholangiocarcinoma with transarterial chemoembolization and an unusual progression with cardiac involvement

Folia Med (Plovdiv). 2023 Apr 30;65(2):326-330. doi: 10.3897/folmed.65.e76329.

Abstract

Intrahepatic cholangiocarcinoma is a rare type of cancer that is usually discovered at an advanced stage where surgical treatment is not an option. When compared to standard systemic therapy, transarterial chemoembolization (TACE) can provide a survival benefit to unresectable patients. Extrahepatic tumor spread is not rare, but cardiac involvement is an unusual complication.We present the case of a 56-year-old man with histologically proven intrahepatic cholangiocarcinoma. Oncologic risk factors include hepatitis B and liver cirrhosis. Being in an unresectable stage of the disease, three TACE procedures were performed. Partial response was achieved (according to RECIST) leading to a 16-month survival. However, disease progression was present, with unusual heart metastases.TACE can bring a survival benefit to unresectable cholangiocarcinoma patients. Defining the best disease stages in which TACE can be implemented and introducing it as part of standard treatment guidelines still presents a challenge.

Keywords: cardiac metastases; intrahepatic cholangiocarcinoma; transarterial chemoembolization.

Publication types

  • Case Reports

MeSH terms

  • Bile Duct Neoplasms* / therapy
  • Bile Ducts, Intrahepatic / pathology
  • Carcinoma, Hepatocellular*
  • Chemoembolization, Therapeutic* / adverse effects
  • Chemoembolization, Therapeutic* / methods
  • Cholangiocarcinoma* / therapy
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Male
  • Middle Aged
  • Treatment Outcome